FOR IMMEDIATE RELEASE
LABOPHARM'S ONCE-DAILY TRAMADOL APPROVED IN SOUTH KOREA AND
– Company Enters Into Marketing Partnership for Once-Daily Tramadol for Turkey –
LAVAL, Quebec (February 13, 2008) – Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that its once-daily
tramadol product has received regulatory approval from the Korea Food and Drug Administration, which allows for the
marketing and sale of Labopharm's once-daily tramadol product in South Korea, and from the Australian Department of Health
and Aging, which allows for the marketing and sale of Labopharm's once-daily tramadol product in Australia.
"Approval in South Korea and Australia brings the number of countries in which our product has been approved to 27," said
James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "South Korea and Australia are important
components of the global commercialization plan for our product. We are now working with our marketing partners in both
countries towards the launches of our product later this year."
Labopharm completed licensing and distribution agreements for its once-daily tramadol product for South Korea with WhanIn
Pharmaceutical Co., Ltd last year, and for Australia with iNova Pharmaceuticals (Australia) Pty Limited earlier this year. The
Company expects its product to be launched in South Korea and Australia later this year.
Marketing Partnership for Once-Daily Tramadol for Turkey
Labopharm also announced today that it has signed a licensing and distribution agreement for its once-daily tramadol product
for Turkey with Dr. F. Frik Ilac San. Ve Tic. A.S.
Under terms of the agreement, Dr. F. Frik will have the exclusive right to market and sell Labopharm's once-daily tramadol
product in Turkey. Labopharm will supply Dr. F. Frik with finished packaged product and will receive revenue from the sale of
such finished packaged product at rates commensurate with those of previous licensing and distribution agreements that